Dormant viruses dodge the immune system, and although these viruses don’t actively replicate, the problem is that they also don’t produce a chemical signal which would tell the antiretroviral therapy (ART) to attack them.
Adverse side effects are a potential risk with nearly every medication, so scientists from the University of Oxford in England looked at if this phenomenon occurs in common drugs that are used to treat the human immunodeficiency virus (HIV).
There are groups of people who are more likely to become infected with the human immunodeficiency virus (HIV) and, therefore, should be taking pre-exposure prophylaxis (PrEP). But are high-risk, HIV-negative people actually taking the preventive medication?
Men over the age of 50 who have human immunodeficiency virus (HIV) and who are adherent to an antiretroviral therapy (ART) regimen are at risk for cognitive decline, according to the results of a recent study.
The news that physicians in Princeton, NJ were confronting an outbreak of hepatitis C in young people who were also using heroin shocked this affluent, mostly white community. Ronald Nahass, MD, talks about how it occurred and what needs to happen next.